XTL Biopharmaceuticals LTD ADR reports a Return on Equity (ROE) of 695.67%.

What is XTLB's dividend yield?

XTL Biopharmaceuticals LTD ADR offers a dividend yield of 0.00%.

What is XTLB's Quality Score?

Our AI rates XTLB's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy XTLB?

Our AI Timing Score for XTLB is 6 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does XTLB belong to?

XTL Biopharmaceuticals LTD ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

XTL Biopharmaceuticals LTD ADR (XTLB) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

XTLB AI Analysis Summary

Our AI summary for XTLB: XTL Biopharmaceuticals LTD ADR (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 695.67%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 6/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

XTLB

XTL Biopharmaceuticals LTD ADR

US:NASDAQ STOCK Healthcare >> Biotechnology News 87

USD 2.85

-0.03 (-1.04%) Day Change

Watchlist Portfolio Compare Chart

-1.06

D/E

695.7%

ROE

-1,064.5%

ROA

0.00%

Div Yield

Data partially updated

XTL BIOPHARMACEUTICALS LTD ADR
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.85 Price -0.03 (-1.04%) Day Change	NEWS SCORE: 87

XTLB, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

51%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	87
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.85
PBV / Sector	-27.86 / 44,105.10
Earning Per Share	-0.71

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.02 M GREAT
Average 1W Daily Value	0.02 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-238.78 / 97.23
NPM Average (%) / Sector	-57.61 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-1,064.46 / 185,260.64
ROA Average (%) / Sector	-1,061.39 / 36,684.64
ROA Change Average (%) / Sector	12,732.27 / 422,221.42 GOOD
ROE (%) / Sector	695.67 / 243,761.81 GREAT
ROE Average (%) / Sector	677.34 / 48,758.38 GREAT
ROE Change Average (%) / Sector	2,161.54 / 424,967.86 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:56
Symbol	XTLB
Name	XTL BIOPHARMACEUTICALS LTD ADR
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	2.46 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	7.08 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 85 Medinat Hayehudim St., Herzliya, Israel, 4676670

Phone: 972 5 4228 8897

Website: https://www.xtlbio.com

Sector: Healthcare >> Biotechnology

Description: XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.